RhumbLine Advisers’s Niagen Bioscience NAGE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $199K | Buy |
62,536
+1,960
| +3% | +$7.95K | ﹤0.01% | 3278 |
|
|
2026
Q1 | $267K | Sell |
60,576
-1,987
| -3% | -$10.7K | ﹤0.01% | 2971 |
|
|
2025
Q4 | $398K | Sell |
62,563
-10,642
| -15% | -$74K | ﹤0.01% | 2801 |
|
|
2025
Q3 | $683K | Sell |
73,205
-2,131
| -3% | -$21.5K | ﹤0.01% | 2480 |
|
|
2025
Q2 | $1.09M | Buy |
75,336
+7,916
| +12% | +$78.2K | ﹤0.01% | 2202 |
|
|
2025
Q1 | $465K | Buy |
67,420
+11,461
| +20% | +$72K | ﹤0.01% | 2624 |
|
|
2024
Q4 | $297K | Buy |
55,959
+14,803
| +36% | +$81K | ﹤0.01% | 2992 |
|
|
2024
Q3 | $150K | Sell |
41,156
-4,363
| -10% | -$13.7K | ﹤0.01% | 3368 |
|
|
2024
Q2 | $124K | Buy |
+45,519
| New | +$152K | ﹤0.01% | 3446 |
|
|
2022
Q2 | – | Sell |
-47,049
| Closed | -$116K | – | 3257 |
|
|
2022
Q1 | $116K | Buy |
47,049
+640
| +1% | +$1.75K | ﹤0.01% | 2860 |
|
|
2021
Q4 | $174K | Sell |
46,409
-346
| -0.7% | -$1.87K | ﹤0.01% | 2863 |
|
|
2021
Q3 | $293K | Buy |
46,755
+1,650
| +4% | +$13.6K | ﹤0.01% | 2775 |
|
|
2021
Q2 | $445K | Sell |
45,105
-1,191
| -3% | -$10.4K | ﹤0.01% | 2613 |
|
|
2021
Q1 | $432K | Sell |
46,296
-1,260
| -3% | -$9.99K | ﹤0.01% | 2558 |
|
|
2020
Q4 | $228K | Buy |
47,556
+3,030
| +7% | +$14.8K | ﹤0.01% | 2785 |
|
|
2020
Q3 | $179K | Sell |
44,526
-7,030
| -14% | -$33.9K | ﹤0.01% | 2721 |
|
|
2020
Q2 | $237K | Buy |
51,556
+3,672
| +8% | +$16.4K | ﹤0.01% | 2689 |
|
|
2020
Q1 | $156K | Hold |
47,884
| – | – | ﹤0.01% | 2663 |
|
|
2019
Q4 | $206K | Buy |
47,884
+97
| +0.2% | +$345 | ﹤0.01% | 2737 |
|
|
2019
Q3 | $188K | Sell |
47,787
-15
| -0% | -$64 | ﹤0.01% | 2765 |
|
|
2019
Q2 | $222K | Buy |
47,802
+306
| +0.6% | +$1.3K | ﹤0.01% | 2750 |
|
|
2019
Q1 | $199K | Sell |
47,496
-1,015
| -2% | -$3.66K | ﹤0.01% | 2748 |
|
|
2018
Q4 | $166K | Buy |
48,511
+16,863
| +53% | +$58.6K | ﹤0.01% | 2789 |
|
|
2018
Q3 | $136K | Sell |
31,648
-292
| -0.9% | -$1.25K | ﹤0.01% | 2822 |
|
|
2018
Q2 | $118K | Buy |
+31,940
| New | +$121K | ﹤0.01% | 2855 |
|
|
2017
Q2 | – | Sell |
-53,053
| Closed | -$143K | – | 2963 |
|
|
2017
Q1 | $143K | Buy |
53,053
+30,739
| +138% | +$87.2K | ﹤0.01% | 2726 |
|
|
2016
Q4 | $74K | Sell |
22,314
-17,087
| -43% | -$46.4K | ﹤0.01% | 2810 |
|
|
2016
Q3 | $117K | Buy |
39,401
+6,500
| +20% | +$23.9K | ﹤0.01% | 2793 |
|
|
2016
Q2 | $136K | Buy |
+32,901
| New | +$156K | ﹤0.01% | 2859 |
|
Other funds holding NAGE
SW
TCM
RhumbLine Advisers's NAGE Position: Q2 2026 in Review
RhumbLine Advisers increased its Niagen Bioscience (NAGE) stake by 3.2% in Q2 2026, buying an estimated $7.95K and bringing the position to 62,536 shares worth $199K. The position accounts for ﹤0.01% of the portfolio, ranked #3278.
RhumbLine Advisers first reported a position in NAGE in Q2 2016 and has held it in 29 quarters since. The position peaked at $1.09M in Q2 2025. 139 funds tracked by Wall St. Rank hold NAGE as of Q2 2026.
- RhumbLine Advisers held 62,536 shares of Niagen Bioscience worth $199K as of Q2 2026.
- RhumbLine Advisers bought 1,960 Niagen Bioscience shares in Q2 2026, an estimated $7.95K.
- Niagen Bioscience made up ﹤0.01% of RhumbLine Advisers's portfolio in Q2 2026, its #3278 holding.
- RhumbLine Advisers first reported a position in Niagen Bioscience in Q2 2016 and has held it in 29 quarters since.
- RhumbLine Advisers's Niagen Bioscience position peaked at $1.09M in Q2 2025.
- 139 funds tracked by Wall St. Rank held Niagen Bioscience as of Q2 2026.
Based on RhumbLine Advisers's 13F filing for Q2 2026, filed 12 Aug 2026.